Changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes

doi:10.12092/j.issn.1009-2501.2025.08.009

Abstract

Abstract: AIM: To explore the changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes. METHODS: Twenty-six patients with type 2 diabetes mellitus complicated with coronary heart disease were selected to compare the changes of glucose and lipid metabolism indexes and intestinal flora (high-throughput sequencing technique) before and after liraglutide treatment, and to analyze the correlation between glucose and lipid metabolism indexes and intestinal flora. RESULTS: Compared with those before treatment, the indexes of glucose metabolism and lipid metabolism in the patients were significantly decreased (P<0.01). Liraglutide had no significant effect on the diversity of intestinal flora (P>0.05), but can significantly change the composition of intestinal flora (P<0.05). While beneficial bacteria such as Lachnospiraceae increased significantly, it significantly reduced the abundance of pathogenic bacteria such as Escherichia_Shigella (P<0.05), and promoted the production of short-chain fatty acids and body metabolism. CONCLUSION: Lilalutide can affect the composition of intestinal flora in type 2 diabetes patients with coronary heart disease, and then participate in the regulation of glucose and lipid metabolism.

Key words: type 2 diabetes, coronary heart disease, intestinal flora, liraglutide

CLC Number:

R587.1

XING Ying, ZHENG Rongjiong, JIANG Chunhui, Mayila·kahaer, Muhuyati·wulasihan. Changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1084-1091.

References

[1] Chen J, Yin D, Dou K.Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions[J]. Cardiovasc Diabetol, 2023, 22. DOI:10.1186/s12933-023-01875-8.
[2] Luo H, Huemer MT, Petrera A, et al.Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study[J]. Cardiovasc Diabetol, 2024, 23(1). Doi:10.1186/s12933-024-02143-z.
[3] Cai Y, Li Y, Xiong Y, et al.Diabetic foot exacerbates gut mycobiome dysbiosis in adult patients with type 2 diabetes mellitus: revealing diagnostic markers[J]. Nutr Diabetes, 2024, 14(1): 71.
[4] 邢英. GLP-1通过调节脂代谢基因及肠道菌群改善非酒精性脂肪性肝病的机制研究 [D].乌鲁木齐: 新疆医科大学, 2021.
[5] 邢英, 郑嵘炅, 姜春晖, 等. 二甲双胍与利拉鲁肽对超重2型糖尿病患者肠道菌群的影响[J]. 传染病信息, 2021, 34(1): 56-62.
[6] Ying X, Rongjiong Z, Kahaer M, et al.Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease[J]. Front Microbiol, 2023, 14: 1088187.
[7] Li J, Wang M, Ma S, et al.Association of gastrointestinal microbiome and obesity with gestational diabetes mellitus-an updated globally based review of the high-quality literatures[J]. Nutr Diabetes, 2024, 14(1). DOI:10.1038/s41387-024-00291-5.
[8] Caruso P, Ida Maiorino M, Longo M, et al.Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the stardust randomized clinical trial[J]. JAMA Network Open, 2024, 7(3): 12. DOI:10.1001/jamanetworkopen.2024.1545.
[9] Wu H, Tremaroli V, Bckhed F.Linking microbiota to human diseases: a systems biology perspective[J]. Trends Endocrinol Metab, 2015, 26(12): 758-770.
[10] 张爱敏, 高宇, 孙启天, 等. 女性2型糖尿病合并冠心病患者肠道菌群特征及相关性分析[J]. 中华内分泌代谢杂志, 2022, 38(2): 100-104.
[11] 彭威风, 张帆, 杨若言, 等. 降糖药对肠道菌群组成和多样性的影响[J]. 中国微生态学杂志, 2022, 34(4): 485-488, 492.
[12] Louis P, Flint HJ.Formation of propionate and butyrate by the human colonic microbiota[J]. Environ Microbiol, 2017, 19(1): 29-41.
[13] Violi F, Cammisotto V, Bartimoccia S, et al.Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease[J]. Nat Rev Cardiol, 2023, 20(1): 24-37.
[14] Zhang B, Wang X, Xia R, et al. Gut microbiota in coronary artery disease: a friend or foe? [J]. Bioscience Rep, 2020, 40(5): BSR20200454.
[15] Nowrouzi-Sohrabi P, Soroush N, Tabrizi R, et al.Effect of liraglutide on cardiometabolic risk profile in people with coronary artery disease with or without type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials[J]. Front Pharmacol, 2021, 12: 618208.
[16] Al Bataineh M, Künstner A, Dash N, et al.Uncovering the relationship between gut microbial dysbiosis, metabolomics, and dietary intake in type 2 diabetes mellitus and in healthy volunteers: a multi-omics analysis[J]. Sci Rep, 2023, 13: 17943.
[17] Kang L, Li P, Wang D, et al.Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia[J]. Sci Rep, 2021, 11(1): 4628.
[18] Jiang Z, Zhuo LB, He Y, et al.The gut microbiota-bile acid axis links the positive association between chronic insomnia and cardiometabolic diseases[J]. Nat Commun, 2022, 13(1): 3002.
[19] Zhang J.Microbial stars: shedding light on gut microbes'role in insulin resistance and innovative diabetes therapies[J]. Gut Microbes, 2024, 16(1): 2307581.
[20] Baars D, Fondevila M, Meijnikman A, et al.The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes[J]. Cell Host Microbe, 2024, 32(8): 1280-1300.